Medical and psychiatric implications of generic drugs

Bruce I. Diamond, John W Albrecht

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Among the most controversial issues surrounding the use of generic drugs is the reliance on bioavailability data to approve generic products. Bioequivalence does not necessarily translate into therapeutic equivalence. In some cases, because of the broad interpretation of drug equivalence, patients may not be receiving adequate amounts of medication, while others may be receiving toxic doses. In contrast, rigorous rules exist for the approval of brand-name medications. Resolving the generic drug standard issue by adopting stricter guidelines for generic drug approval based on clinical efficacy and toxicity data rather than on the bioequivalence standard currently being used would more likely result in safer, more effective patient care. Economic burdens for postmarketing research should be shared jointly by the research-oriented and generic drug companies. Such a policy would ensure continued research and new drug development. This paper reviews major scientific, economic, social, and legal issues involved in generic drug use with particular emphasis on the psychotropic drugs.

Original languageEnglish (US)
Pages (from-to)92-98
Number of pages7
JournalPsychopathology
Volume20
DOIs
StatePublished - Jan 1 1987

Fingerprint

Generic Drugs
Psychiatry
Therapeutic Equivalency
Economics
Research
Drug Approval
Poisons
Psychotropic Drugs
Pharmaceutical Preparations
Biological Availability
Names
Patient Care
Guidelines

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Medical and psychiatric implications of generic drugs. / Diamond, Bruce I.; Albrecht, John W.

In: Psychopathology, Vol. 20, 01.01.1987, p. 92-98.

Research output: Contribution to journalArticle

Diamond, Bruce I. ; Albrecht, John W. / Medical and psychiatric implications of generic drugs. In: Psychopathology. 1987 ; Vol. 20. pp. 92-98.
@article{c7e0ef9c27f24f8d839dcb9a265fcb05,
title = "Medical and psychiatric implications of generic drugs",
abstract = "Among the most controversial issues surrounding the use of generic drugs is the reliance on bioavailability data to approve generic products. Bioequivalence does not necessarily translate into therapeutic equivalence. In some cases, because of the broad interpretation of drug equivalence, patients may not be receiving adequate amounts of medication, while others may be receiving toxic doses. In contrast, rigorous rules exist for the approval of brand-name medications. Resolving the generic drug standard issue by adopting stricter guidelines for generic drug approval based on clinical efficacy and toxicity data rather than on the bioequivalence standard currently being used would more likely result in safer, more effective patient care. Economic burdens for postmarketing research should be shared jointly by the research-oriented and generic drug companies. Such a policy would ensure continued research and new drug development. This paper reviews major scientific, economic, social, and legal issues involved in generic drug use with particular emphasis on the psychotropic drugs.",
author = "Diamond, {Bruce I.} and Albrecht, {John W}",
year = "1987",
month = "1",
day = "1",
doi = "10.1159/000284528",
language = "English (US)",
volume = "20",
pages = "92--98",
journal = "Psychopathology",
issn = "0254-4962",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Medical and psychiatric implications of generic drugs

AU - Diamond, Bruce I.

AU - Albrecht, John W

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Among the most controversial issues surrounding the use of generic drugs is the reliance on bioavailability data to approve generic products. Bioequivalence does not necessarily translate into therapeutic equivalence. In some cases, because of the broad interpretation of drug equivalence, patients may not be receiving adequate amounts of medication, while others may be receiving toxic doses. In contrast, rigorous rules exist for the approval of brand-name medications. Resolving the generic drug standard issue by adopting stricter guidelines for generic drug approval based on clinical efficacy and toxicity data rather than on the bioequivalence standard currently being used would more likely result in safer, more effective patient care. Economic burdens for postmarketing research should be shared jointly by the research-oriented and generic drug companies. Such a policy would ensure continued research and new drug development. This paper reviews major scientific, economic, social, and legal issues involved in generic drug use with particular emphasis on the psychotropic drugs.

AB - Among the most controversial issues surrounding the use of generic drugs is the reliance on bioavailability data to approve generic products. Bioequivalence does not necessarily translate into therapeutic equivalence. In some cases, because of the broad interpretation of drug equivalence, patients may not be receiving adequate amounts of medication, while others may be receiving toxic doses. In contrast, rigorous rules exist for the approval of brand-name medications. Resolving the generic drug standard issue by adopting stricter guidelines for generic drug approval based on clinical efficacy and toxicity data rather than on the bioequivalence standard currently being used would more likely result in safer, more effective patient care. Economic burdens for postmarketing research should be shared jointly by the research-oriented and generic drug companies. Such a policy would ensure continued research and new drug development. This paper reviews major scientific, economic, social, and legal issues involved in generic drug use with particular emphasis on the psychotropic drugs.

UR - http://www.scopus.com/inward/record.url?scp=0023462236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023462236&partnerID=8YFLogxK

U2 - 10.1159/000284528

DO - 10.1159/000284528

M3 - Article

VL - 20

SP - 92

EP - 98

JO - Psychopathology

JF - Psychopathology

SN - 0254-4962

ER -